Abiopharma

🔍 Conder Keenan Michael (Executive)

Company: SentinelOne, Inc. (S)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 9,074 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 566,258.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 13,715 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 579,973.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 5,578 shares of Class A Common Stock at $13.37 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 574,395.00 | transaction_form_type: 4 | Footnotes: F6, F4

Footnotes:

• F1: The reported transaction represents the certification of achievement of the second tranche of a performance-based restricted stock unit award granted to the reporting person by the Issuer's compensation committee on March 15, 2024 (the "2024 PRSU Award").
• F2: Vesting of each respective tranche of each PRSU Award (defined below) is based on the achievement of pre-determined corporate performance milestones for such PRSU Award and is subject to the reporting person's continued service through the certification date of achievement of the relevant tranche.
• F3: On March 23, 2026 (the "Certification Date"), the Issuer's compensation committee certified achievement of the tranches of the PRSU Awards reported herein, resulting in one-fourth of each award becoming earned at 90.2% of the respective target amounts granted. The performance restricted stock units comprising the tranches so earned are fully vested and may be settled for shares of the Issuer's Class A common stock on the Certification Date.
• F4: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
• F5: The reported transaction represents the certification of achievement of the first of four tranches of a performance-based restricted stock unit award granted to the reporting person by the Issuer's compensation committee on April 14, 2025 (the "2025 PRSU Award" and, together with the 2024 PRSU Award, the "PRSU Awards").
• F6: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based Restricted Stock Units, and it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.